Myo-Inositol 600mg + Metformin Hydrochloride 500mg Sustained Release per tablet
METSIFER PLUS is a pharmacologically sophisticated combination targeting the central hormonal and metabolic dysfunctions of Polycystic Ovary Syndrome (PCOS) and insulin resistance through two complementary mechanisms.
Myo-Inositol 600mg: Myo-inositol is a natural polyol (cyclohexane polyol) that is the most important second messenger in the insulin signalling cascade. It serves as the precursor for phosphatidylinositol phosphates (PIPs) — the intracellular lipid mediators activated when insulin binds its receptor. In PCOS, inositol deficiency or signalling dysfunction causes insulin resistance at the cellular level — the ovarian theca cells fail to respond normally to insulin and FSH signals, leading to excessive androgen production (hyperandrogenism), anovulation, and the characteristic polycystic ovarian morphology.
Myo-inositol supplementation restores normal insulin signalling in ovarian cells, reducing insulin-stimulated androgen production, improving FSH sensitivity, and restoring ovulatory function. At 600mg per tablet (standard dose is 2–4gm/day, achievable with 4–8 tablets), myo-inositol supplementation has clinical evidence for: reducing hyperandrogenism biomarkers (DHEAS, free testosterone, LH/FSH ratio), restoring menstrual cyclicity, improving oocyte quality in IVF cycles, and reducing first-trimester miscarriage rates in PCOS patients.
Metformin Hydrochloride 500mg Sustained Release: Metformin is the foundational insulin sensitiser for PCOS management. Its primary mechanism involves activation of AMP-activated protein kinase (AMPK) in the liver — reducing hepatic glucose output (gluconeogenesis), increasing peripheral glucose uptake in muscle (through GLUT4 translocation), and improving insulin sensitivity by reducing hepatic and peripheral insulin resistance. In the PCOS context, metformin's insulin sensitisation reduces the hyperinsulinaemia that drives ovarian androgen overproduction, restores hypothalamic-pituitary-ovarian axis function (reducing LH hyperpulsatility), and improves menstrual cyclicity.
The SR formulation releases metformin gradually over 8–12 hours, reducing peak plasma concentrations that cause the nausea and GI side effects that limit compliance with immediate-release metformin — a critical advantage for the long-term PCOS management that may be required for years in reproductive-age women.
METSIFER PLUS is specifically indicated for Polycystic Ovary Syndrome (PCOS) management — the most common endocrine disorder in women of reproductive age, affecting 5–15% of women globally.
PCOS — Insulin Resistance and Hormonal Dysregulation (Primary): Myo-inositol + metformin addresses both the cellular inositol signalling dysfunction and the systemic insulin resistance that together drive PCOS pathophysiology. The combination is more effective than either agent alone for reducing hyperandrogenism, restoring menstrual regularity, and improving metabolic parameters.
PCOS-Related Infertility: Restoring ovulatory function in anovulatory PCOS is essential for natural conception and IVF outcomes. Myo-inositol specifically improves oocyte quality — a critical factor in IVF success rates in PCOS patients. Used as adjunct to ovulation induction with letrozole or clomiphene.
PCOS-Related Metabolic Syndrome: Abdominal obesity, hypertriglyceridaemia, and impaired glucose tolerance — metformin's insulin sensitisation and myo-inositol's inositol-phosphoglycan signalling together improve metabolic parameters beyond what metformin achieves alone.
Pre-Diabetes in PCOS: Metformin 500mg SR is the evidence-based intervention for preventing progression from impaired glucose tolerance to T2DM in PCOS patients at metabolic risk.
Gestational Diabetes Prevention: Myo-inositol supplementation in PCOS patients during pregnancy reduces gestational diabetes risk — an emerging and evidence-supported indication.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
PCOS is the most common endocrine disorder in women of reproductive age, affecting an estimated 20–25 million Indian women. Its management requires simultaneous attention to hormonal dysregulation (hyperandrogenism, anovulation), insulin resistance (the root metabolic driver), and fertility optimisation — a multi-dimensional therapeutic challenge that myo-inositol + metformin addresses comprehensively.
The rationale for combining myo-inositol with metformin is supported by clinical evidence showing that the combination reduces hyperandrogenism and restores menstrual cyclicity more effectively than metformin alone, while myo-inositol's insulin-sensitising mechanism works upstream of metformin's AMPK activation — providing genuinely complementary coverage.
For gynaecologists and reproductive endocrinologists who manage PCOS — one of their most common clinical presentations — METSIFER PLUS provides a pharmacologically justified combination in a convenient single-tablet format that simplifies the management of a condition requiring long-term, multi-mechanism treatment.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.